Perimeter Medical AI Gains FDA Approval for First-of-its-Kind Breast Cancer Imaging Tool

Key Facts

1Perimeter Medical received FDA Premarket Approval (PMA) for Claire, the first AI-enabled imaging device for breast cancer margin assessment.

2The technology demonstrated a statistically significant reduction in patients with residual cancer post-surgery compared to standard care.

3The company plans a nationwide launch of the tool to help reduce the need for repeat surgeries.

Perimeter Medical Imaging AI has secured Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for its "Claire" device. This milestone marks the first time an AI-enabled imaging tool has been cleared for intraoperative breast cancer margin assessment in the United States. Clinical trials demonstrated a statistically significant reduction in residual cancer post-surgery compared to current standard care practices. By helping surgeons detect difficult-to-see cancer during procedures, the technology aims to drastically lower the rate of repeat surgeries. The company plans to initiate a nationwide launch of the tool, transitioning from a clinical-stage entity to a commercial-stage MedTech player. This regulatory success is expected to drive significant investor interest in PINK as it begins its commercial rollout in the U.S. market.